Clinical Trials Logo

Leukomalacia, Periventricular clinical trials

View clinical trials related to Leukomalacia, Periventricular.

Filter by:

NCT ID: NCT00413946 Completed - Cerebral Palsy Clinical Trials

Does Erythropoietin Improve Outcome in Very Preterm Infants?

Start date: January 2006
Phase: Phase 2
Study type: Interventional

The main goal of this trial is to investigate whether early administration of human erythropoietin (EPO) in very preterm infants improves neurodevelopmental outcome at 24 months corrected age. This study is designed as randomized, double-masked, placebo controlled multicenter study involving at least 420 patients.

NCT ID: NCT00375908 Completed - Clinical trials for Hypoxia-Ischemia, Brain

Umbilical Cord Blood Proteomic Analysis and Neonatal Brain Injury

Start date: October 2005
Phase: N/A
Study type: Observational

The investigators propose to compare the proteomic analysis of umbilical venous blood from neonates with brain injury to gestational age matched noninjured controls. After delivery an umbilical arterial gas and a 10 ml umbilical venous sample are obtained, then the remainder of the cord blood is discarded. The investigators plan to use this cord blood that would otherwise be discarded to perform our proteomic analysis. The investigators will use up to 20 ml of cord blood per delivery. This will be a 5 year study during which time the investigators hope to analyze 450 infants at Johns Hopkins Hospital and Bayview Medical Center. The investigators will obtain an umbilical venous sample from infants born at < 34 weeks gestation. For infants born at > 34 weeks the investigators will obtain an umbilical venous sample for any infant suspected to be at risk for neurologic injury by having a diagnosis of chorioamnionitis during labor, nonreassuring fetal heart rate tracing at the time of delivery, or a 5 minute Apgar < 7. For the infants born at < 34 weeks the brain injured infants will be compared to gestational age matched controls without brain injury. For the infants born at > 34 weeks, each infant later confirmed to have neurologic morbidity will be compared to a gestational age matched noninjured control. The investigators hope to use proteomic analysis to determine if there are measurable differences in protein expression between the 2 groups.

NCT ID: NCT00369005 Completed - Anemia Clinical Trials

Liberal Versus Restrictive Transfusion Guidelines for Preterm Infants

Start date: December 1992
Phase: N/A
Study type: Interventional

The purpose of this study was to determine whether restrictive guidelines for red blood cell (RBC) transfusions for preterm infants can reduce the number of transfusions without adverse consequences.

NCT ID: NCT00303082 Terminated - Sepsis Clinical Trials

Probiotics for the Prevention of Premature Birth and Neonatal Related Morbidity

Start date: January 2006
Phase: Phase 3
Study type: Interventional

The trial intends to evaluate the efficacy of specially designed probiotics to prevent premature birth and related neonatal morbidity associated to intra-uterine infection. The tested probiotics are efficacious to decrease the prevalence of bacterial vaginosis. The study hypothesis is that the early administration of those probiotics to pregnant women with bacterial vaginosis can prevent premature birth through antibiotic activity and modulation of the immune response to infection.

NCT ID: NCT00120588 Completed - Preterm Birth Clinical Trials

Neuroprotection by Magnesium Sulfate Given to Women at Risk of Very Preterm Birth

Start date: July 1997
Phase: Phase 4
Study type: Interventional

Magnesium is neuroprotective in neonatal animal models of acquired hypoxic-ischemic and/or inflammatory cerebral lesions. It is associated with a significant reduction of perinatal death and cerebral palsy in some observational studies. The objective of the study is to assess if prenatal magnesium sulfate given to women at risk of preterm birth before 33 week's gestation is neuroprotective.

NCT ID: NCT00014989 Completed - Cerebral Palsy Clinical Trials

Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)

BEAM
Start date: December 1997
Phase: Phase 3
Study type: Interventional

As many more premature infants survive, the numbers of these infants with health problems increases. The rate of cerebral palsy (CP) in extremely premature infants is approximately 20%. Magnesium sulfate, the most commonly used drug in the US to stop premature labor, may prevent CP. This trial tests whether magnesium sulfate given to a woman in labor with a premature fetus (24 to 31 weeks out of 40) will reduce the rate of death or moderate to severe CP in the children at 2 years. The children receive ultrasounds of their brains as infants and attend three follow-up visits over two years to assess their health and development.